Clinical and prognostic significance of e1a2 BCR-ABL1 transcript subtype in chronic myeloid leukemia

[1]  B. George,et al.  Frequency of rare BCR‐ABL1 fusion transcripts in chronic myeloid leukemia patients , 2017, International journal of laboratory hematology.

[2]  L. Medeiros,et al.  Clinical significance of trisomy 8 that emerges during therapy in chronic myeloid leukemia , 2016, Blood Cancer Journal.

[3]  H. Kantarjian,et al.  Risk stratification of chromosomal abnormalities in chronic myelogenous leukemia in the era of tyrosine kinase inhibitor therapy. , 2016, Blood.

[4]  Mario Cazzola,et al.  The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. , 2016, Blood.

[5]  Z. Estrov,et al.  Impact of BCR-ABL transcript type on outcome in patients with chronic-phase CML treated with tyrosine kinase inhibitors. , 2016, Blood.

[6]  M. Ladetto,et al.  Prognostic Impact of p190 and p210 Co-Expression at Diagnosis in Chronic Myeloid Leukemia (CML) Patients Treated with Imatinib , 2014 .

[7]  Martin C. Müller,et al.  Distinct characteristics of e13a2 versus e14a2 BCR-ABL1 driven chronic myeloid leukemia under first-line therapy with imatinib , 2014, Haematologica.

[8]  H. Kantarjian,et al.  Improved survival in chronic myeloid leukemia since the introduction of imatinib therapy: a single-institution historical experience. , 2011, Blood.

[9]  H. Kantarjian,et al.  Prognostic impact of deletions of derivative chromosome 9 in patients with chronic myelogenous leukemia treated with nilotinib or dasatinib , 2011, Cancer.

[10]  M. Baccarani,et al.  Deletions of the derivative chromosome 9 do not influence the response and the outcome of chronic myeloid leukemia in early chronic phase treated with imatinib mesylate: GIMEMA CML Working Party analysis. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[11]  C. Bloomfield,et al.  The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes. , 2009, Blood.

[12]  R. Reinhardt,et al.  A multiplex PCR for improved detection of typical and atypical BCR-ABL fusion transcripts. , 2008, Leukemia research.

[13]  R. Kawaguchi,et al.  Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). , 2002, Internal medicine.

[14]  S. Ohtake.  Chronic myelogenous leukemia with p190BCR-ABL expression: the missing link with monocytosis. , 2002, Internal medicine.

[15]  M. Hur,et al.  Lymphoid preponderance and the absence of basophilia and splenomegaly are frequent in m-bcr-positive chronic myelogenous leukemia , 2002, Annals of Hematology.

[16]  R. Kawaguchi,et al.  Philadelphia chromosome-positive chronic myeloid leukemia expressing p190(BCR-ABL). , 2002, Internal medicine.

[17]  E. Morra,et al.  The possible influences of B2A2 and B3A2 BCR/ABL protein structure on thrombopoiesis in chronic myeloid leukaemia. , 2000, European journal of cancer.